In an IL-23/Th17-driven neutrophilic inflammation model, this subpopulation can bind to neutrophils in a CD9-dependent manner and degrade ATP via CD39 to inhibit the formation of NETosis and the activation of Th17 cells, thereby alleviating airway inflammation. The gene discussed is CD9; the disease is inflammatory response.